NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 100 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


Immune Checkpoint Inhibitor;
Solid Tumor

Recruitment Keyword(s)



Solid Tumors;
Rare Cancers

Investigational Drug(s)


Investigational Device(s)



Drug: Atezolizumab
Drug: Tiragolumab

Supporting Site

National Cancer Institute


About 20% of newly diagnosed cancers in the United States are considered to be rare; that is, they occur in less than 6 out of 100,000 people. People with rare cancers have fewer treatment options and lower survival rates than people with more common cancers.


To test 2 drugs (atezolizumab and tiragolumab) in people with advanced rare cancers.


People aged 18 years and older with advanced rare solid tumors that have not responded to treatment or for which no treatment exists.


Participants will have a physical exam. They will have blood and urine tests and tests of their heart function. They will answer questions about their daily activities. Their tumors will be measured using imaging scans. They will have a biopsy: A small sample of tissue will be removed from the tumor.

Both study drugs are administered through a tube attached to a needle inserted into a vein in the arm (IV infusion). Infusion of each drug takes about 1 hour. Participants will be monitored 1 to 2 hours after each infusion.

Participants will receive the study drugs on the first day of each treatment cycle. Each cycle lasts 21 days. They will have blood and urine tests at each treatment visit.

Participants may remain in the study as long as the drugs are benefitting them.

A tumor biopsy will be required at the start of cycle 3. Imaging scans will be repeated every 2 cycles starting with cycle 4.

Participants will be monitored for 30 days after their last treatment.

--Back to Top--



-Patients must have histologically confirmed rare solid tumors that have progressed on standard therapy or for whom there is no standard of care therapy. Other rare tumor types may be acceptable at the discretion of the PI.

--Patients must not be eligible for a higher priority study, such as a disease specific study of phase 2 or higher or a randomized study. Specifically, patients with who are eligible for PEP-CTN pediatric trial of atezolizumab and tiragolumab in children, adolescents, and young adults with SMARCB1- or SMARCA4-deficient tumors should be excluded.

-Patients must have measurable disease as defined by RECIST v1.1, with at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >=20 mm (>=2 cm) by chest x-ray or as >=10 mm (>=1 cm) with CT scan, MRI, or calipers by clinical exam).

-Patients must have a tumor site amenable to biopsy.

-Age >=18 years. Because biopsies are mandatory on this trial, patients <18 years of age are excluded.

-ECOG performance status <=2 (Karnofsky >=60%).

-Patients must have adequate organ and marrow function as defined below:

--absolute neutrophil count >=1,500/mcL

--platelets >=100,000/mcL

--INR or aPTT* <=1.5 institutional upper limit of normal (ULN)

--total bilirubin 1.5 x institutional ULN (however, patients with known Gilbert disease who have serum bilirubin level of up to 3 mg/dl may be enrolled)

--AST(SGOT)/ALT(SGPT) <=2.5 (SqrRoot) institutional ULN (AST and/or ALT <=5 <= ULN for patients with liver involvement)

--creatinine <=1.5 X institutional ULN


--creatinine clearance levels >= 30 mL/min/1.73 m2 are permitted as the study agents are not secreted by the kidney

* Patients who receive therapeutic anticoagulation therapy should be on a stable dose.

-Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. For these patients, an HIV viral load test must be completed within 28 days prior to enrollment

-For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.

-Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

-Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for more than >=1 month after treatment of the brain metastases.

-Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.

-Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.

-Willingness to provide biopsy samples for research purposes.

-Administration of atezolizumab and tiragolumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

-Ability to understand and the willingness to sign a written informed consent document.


-Patients who have had prior monoclonal antibody therapy must have completed that therapy >=5 weeks (or 3 half-lives of the antibody, whichever is shorter) prior to enrollment on protocol (minimum of 1 week between prior therapy and study enrollment).

-Patients must have recovered from clinically-significant adverse events of their most recent cancer immunotherapy to grade 1 or less, (with the exception of alopecia and lymphopenia).

-Patients who are receiving any other investigational agents.

-Prior anti-TIGIT therapy is not allowed. However, other prior immune checkpoint inhibitor therapy is permitted, provided it satisfies the conditions.

-History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies (i.e., antibodies with generic names ending in "ximab" or "zumab", respectively) or fusion proteins, not resolved by pre-medication or steroids, leading to subsequent treatment cessation. Patients with a history of allergic reaction to chimeric or humanized antibodies for which symptoms never recurred after subsequent re-challenge may be considered after careful medical history review.

-Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone [>10 mg/day], cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1.

--Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.

--The use of inhaled corticosteroids and systemic mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.

-Patients with uncontrolled intercurrent illness, that would limit compliance with study requirements.

-Pregnant women are excluded from this study because atezolizumab and tiragolumab are investigational agents with unknown potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab, and because it is not known if tiragolumab can be excreted in human milk, breastfeeding should be discontinued if the mother is treated with atezolizumab.

-History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener s granulomatosis, Sj(SqrRoot)(Delta)gren s syndrome, Bell s palsy, Guillain-Barr(SqrRoot)(Copyright) syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis.

--Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.

--Patients with autoimmune hyperthyroid disease not requiring immunosuppressive treatment may be eligible.

--Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.

--Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:

---Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations

---Rash must cover less than 10% of body surface area (BSA)

---Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%)

---No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)

-Patients with active tuberculosis (TB) are excluded.

-Severe infections within 4 weeks prior to Cycle 1, Day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.

-Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1.

-Received oral or intravenous (IV) antibiotics within 2 weeks prior to Cycle 1, Day 1. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection

or chronic obstructive pulmonary disease) are eligible.

-Patients who have undergone major surgical procedures prior to Cycle 1, Day 1 who have not recovered to ECOG performance status <=2 (Karnofsky >=60%).

-Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab.

--Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to Cycle 1, Day 1 or at any time during the study.

--Back to Top--


Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang JCH, Barlesi F, Lee DH, Ares LP, Hsieh RW, Patil NS, Twomey P, Yang X, Meng R, Johnson ML. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13. PMID: 35576957.

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Naoko Takebe, M.D.
National Cancer Institute (NCI)
(240) 541-4515

Murielle Hogu
National Cancer Institute (NCI)

(240) 858-3335

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office

Clinical Trials Number:


--Back to Top--